The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Frits van Rhee

Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences 4301 West Markham

Little Rock

AR 72205 USA

USA

[email]@uams.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences 4301 West Markham, Little Rock, AR 72205 USA, USA. 2008 - 2012
  • University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock, AR 72205, USA. 2005 - 2010

References

  1. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Garg, T.K., Szmania, S.M., Khan, J.A., Hoering, A., Malbrough, P.A., Moreno-Bost, A., Greenway, A.D., Lingo, J.D., Li, X., Yaccoby, S., Suva, L.J., Storrie, B., Tricot, G., Campana, D., Shaughnessy, J.D., Nair, B.P., Bellamy, W.T., Epstein, J., Barlogie, B., van Rhee, F. Haematologica (2012) [Pubmed]
  2. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. van Rhee, F., Fayad, L., Voorhees, P., Furman, R., Lonial, S., Borghaei, H., Sokol, L., Crawford, J., Cornfeld, M., Qi, M., Qin, X., Herring, J., Casper, C., Kurzrock, R. J. Clin. Oncol. (2010) [Pubmed]
  3. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. van Rhee, F., Stone, K., Szmania, S., Barlogie, B., Singh, Z. Clin. Adv. Hematol. Oncol (2010) [Pubmed]
  4. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. van Rhee, F., Szmania, S.M., Dillon, M., van Abbema, A.M., Li, X., Stone, M.K., Garg, T.K., Shi, J., Moreno-Bost, A.M., Yun, R., Balasa, B., Ganguly, B., Chao, D., Rice, A.G., Zhan, F., Shaughnessy, J.D., Barlogie, B., Yaccoby, S., Afar, D.E. Mol. Cancer Ther. (2009) [Pubmed]
  5. Is double autologous stem-cell transplantation appropriate for new multiple myeloma patients?. van Rhee, F. Nature Clinical Practice. Oncology (2008) [Pubmed]
  6. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. van Rhee, F., Szmania, S.M., Zhan, F., Gupta, S.K., Pomtree, M., Lin, P., Batchu, R.B., Moreno, A., Spagnoli, G., Shaughnessy, J., Tricot, G. Blood (2005) [Pubmed]
 
WikiGenes - Universities